Future studies will evaluate the long-term efficacy and safety of febuxostat in more patient populations, and may develop a new generation of xanthine oxidase inhibitors based on its structural optimization to provide more options for the treatment of hyperuricemia. This evidence concerns the gene XDH and hyperuricemia.